Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AutoImmune Myloral PLA for MS planned for late 1997, CEO tells UBS.

Executive Summary

AUTOIMMUNE MYLORAL PLA FOR MS TO BE FILED IN FOURTH QUARTER 1997 assuming positive results from Phase III trials to be completed in May, AutoImmune CEO Robert Bishop, PhD, told analysts at the UBS Securities Life Sciences Conference in New York City Oct. 7. Myloral is an "oral solid dosage formulation of purified myelin from bovine brains," Autoimmune said. The company is seeking an indication for treatment of relapsing/remitting multiple sclerosis.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028984

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel